Fadi Chalhoub

Aug 19, 2024 | mdpi.com | Kevin John |Fadi Chalhoub |Jennifer Chee |Sarah Daoudi

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Feb 16, 2024 | jamanetwork.com | George Bakris |Manish Saxena |Anil Gupta |Fadi Chalhoub

Key PointsQuestion  Does targeting hepatic angiotensinogen synthesis with the RNA interference therapeutic zilebesiran reduce blood pressure in adults with mild to moderate hypertension? Findings  In a phase 2 trial, subcutaneous zilebesiran doses of 150, 300, or 600 mg every 6 months or 300 mg every 3 months significantly decreased systolic blood pressure at 3 and 6 months vs placebo.